Incidence of de novo Lymphoproliferative Disorders and Hematological Malignancies in Liver Transplant Recipients: An Updated Meta-Analysis
Related Experiment Video
Updated: Feb 13, 2026
A Strategy to Identify de Novo Mutations in Common Disorders such as Autism and Schizophrenia
Published on: June 15, 2011
Eyad Gadour1,2, Bogdan Miutescu3, Hadi Kuriry1
1Liver Transplantation Unit, Multiorgan Transplant Centre of Excellence, King Fahad Specialist Hospital, Dammam, Saudi Arabia.
Background:
De novo malignancies are a significant cause of mortality in liver transplant recipients. This systematic review and meta-analysis synthesized evidence regarding the incidence of de novo lymphoid and hematological malignancies.
Methods:
Observational studies that compared the prevalence of hematologic malignancies in liver transplant recipients with the general population were included following searches using relevant keywords in ScienceDirect, PubMed, and Google Scholar. The methodological quality of the included studies was evaluated using the Newcastle-Ottawa Scale, with the overall quality converted into the Agency for Healthcare Research and Quality standards (i.e., poor, fair, and good). The generic inverse variance method was used to pool the standardized incidence ratio (SIR) as risk ratios and their 95% confidence intervals (CI).
Results:
A total of 32 studies were included. Following liver transplantation, post-transplant lymphoproliferative disorder was the most common hematologic malignancy (SIR: 23.06, 95% CI: 4.08-130.04; P < 0.0004), while multiple myeloma was the least common (SIR: 3.10, 95% CI: 2.22-4.34; P < 0.0001). The incidence of non-Hodgkin lymphoma (SIR: 11.05, 95% CI: 8.54-14.28; P < 0.0001) was higher than that of Hodgkin lymphoma (SIR: 7.59, 95% CI: 5.63-11.23; P < 0.0001). The overall risk of hematologic malignancies in liver transplant recipients was significantly higher than in the general population (SIR: 5.83; 95% CI: 2.35-8.05; P < 0.0001).
Conclusion:
This meta-analysis found that after liver transplantation, post-transplant lymphoproliferative disorder (PTLD) is the most prevalent hematological malignancy. Although PTLD and other hematologic malignancies are less prevalent than solid organ nonlymphoid tumors, they significantly affect liver transplant recipient outcomes. Further research is necessary to identify strategies for managing these complications.
Registration:
PROSPERO (Reg. no.: CRD420251131279).
Related Concept Videos
01:08Prevalence and Incidence
Prevalence indicates the proportion of individuals in a population who have a specific disease or health...
01:09Directing Effect of Substituents: meta-Directing Groups
01:21Types of Reports II: Incident or Occurrence Report
Purposes:
In the healthcare industry, reports play a crucial role in documenting incidents within an agency. The primary objective of these reports is to ensure patient safety, uphold the...
02:18Intrinsically Disordered Proteins
01:29Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
01:27Disorders of Erythrocytes
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...